Navigation Links
LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
Date:11/9/2011

THE WOODLANDS, Texas, Nov. 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center will be presenting data from Lexicon's LX2931 Phase 2 proof-of-concept clinical trial at the annual meeting of the American College of Rheumatology on Wednesday, November 9, 2011 in Chicago, Illinois.  LX2931 is an orally-administered small molecule designed to inhibit sphingosine-1-phosphate lyase (S1P), an enzyme in a pathway known to be important in regulating the immune response.  

Results from the Phase 2a study demonstrated a favorable safety profile at all doses tested and suggested that patients with rheumatoid arthritis treated with 150 mg of LX2931 once daily showed improvement in the primary efficacy endpoint of the study, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12.

For more information on this program or to download a copy of the presentation, please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
2. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
3. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
4. Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
5. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
6. Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
7. Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- In part four of a blog series ... a strategic asset, Mary Baxter, MBA, RPh ., ... Innovation Delivery Solutions business, discusses how expanding patient access ... patients. "Every hospital pharmacist knows that filling ... in a value-based healthcare world," Baxter says. "For the ...
(Date:8/29/2014)... ROBLES, Calif. , Aug. 29, 2014  Pacific ... of its new website design . The main ... overhaul that showcases the company,s new services and content ... By implementing a new streamlined design, viewers can now ... metrics for health care practices and create a more ...
(Date:8/29/2014)... 2014 Pixcelldata, the innovative Irish ... announced a major new deal with Dutch based eX-Path, ... expert, Dr. Marius Nap . The ... Congress of Pathology which is taking placing between August ... London where Pixcelldata will demonstrate its ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4PMDS Announces New Website 2Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
... -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... from its ZFP Therapeutic program to develop SB-509, a ... endothelial growth factor (VEGF)-A gene as a treatment for ... drug was well-tolerated in subjects with ALS and that ...
... 17, 2010 The Amgen Foundation and Ashoka,s Changemakers today ... Empowerment competition and launched public online voting in search ... voices, and improve health outcomes. The ten ... from 277 entries received from 40 countries. Online ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 2Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 3Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 4Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 5Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 6Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 7Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 2Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 3Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 4
(Date:8/30/2014)... OH (PRWEB) August 30, 2014 United Theological ... first fully online degree, the Master of Theological Studies (MTS). ... in 2-3 years, is designed for students who wish to ... their understanding and capacity to serve the Church and community. ... degree, but now they can attend classes from any location ...
(Date:8/30/2014)... Daily Gossip reveals in its review a ... You program, who shows a unique formula to get inside ... method says that the program goes beyond mere attraction and ... You review indicates that the program was created by dating ... great techniques to make a man feel emotionally addicted. , ...
(Date:8/30/2014)... The Plastic Surgery Group (PSG) is ... even in the U.S. to provide clients with Vanquish, ... patients’ waists with deep-tissue heating. , Unlike Cryotherapy which ... is more inclusive to target large sections of desired ... panels about one inch away from their body while ...
(Date:8/30/2014)... York, NY (PRWEB) August 30, 2014 ... authentic U.S. Open Tennis Championship tickets in ... customer appreciation promo/coupon code US-OPEN-2014 for all day session, ... seats and group sales for this prestigious Grand Slam ... is below: , 8/30/14 , US Open Tennis Championship: ...
(Date:8/30/2014)... August 30, 2014 Acne is a common problem ... acne is nothing more than a daily nuisance, for some, it ... cases of acne can even lead to dramatic mood swings and ... try anything to clear up their skin. In some cases, that ... money through trial and error, those on a quest for clearer ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Acne Treatment Reviews Added to Popular Treatment Website 2
... white paper that examines various state initiatives to expand access ... and Congress in support of state efforts, was distributed today ... The paper, State Experimentation with Reforms to Expand Access to ... part of any state-based reform. It is a summary of ...
... Ill., Sept. 14 The board of,directors of Abbott ... share. This marks the 335th consecutive quarterly dividend ... is payable Nov. 15, 2007, to,shareholders of record at ... About Abbott Abbott (NYSE: ABT ) is ...
... 14 As the political turmoil,surrounding stem cells rages ... and treatment - that saved his life. John E. ... -, http://www.authorhouse.com ), recounts the courageous five-year battle the,author ... cancer. Settling into a comfortable retirement with his ...
... of Texas Medical Branch at Galveston are trying to ... can also be used to delay delivery in expectant ... would give hope to hundreds of thousands of women ... drug, Digibind, has been prescribed for over 20 years ...
... Sept. 14 People,s United,Financial (Nasdaq: PBCT ) ... Klein, had undergone surgery to address a recurrence of,cancer ... surgery. He reported,in an e-mail to all employees that ... bank in early October. He stated that he is ...
... - Philly-Area Employers Get Moving by Putting on ... AstraZeneca continues,its fight against sedentary lifestyles by ... in Philadelphia to promote,walking and other healthy habits ... a Start! "walkforce" team to participate in,today,s Philadelphia ...
Cached Medicine News:Health News:Internal medicine physicians recommend key elements to guide state initiatives 2Health News:Internal medicine physicians recommend key elements to guide state initiatives 3Health News:The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival 2Health News:AstraZeneca Joins Local Walking Movement 2Health News:AstraZeneca Joins Local Walking Movement 3Health News:AstraZeneca Joins Local Walking Movement 4
... The BioPlex 2200 system is ... platform that can deliver up to ... will initially include a panel of ... in development are in the areas ...
... ASR contains primers and a FAM-labeled probe targeting ... as well as primers and an Alexa 532-labeled ... of HSV Type 2. This ASR requires an ... Alexa reporter dyes like the Cepheid SmartCycler System. ...
... and a FAM-labeled probe that is designed to ... Type 1 and Type 2 polymerase gene. This ... FAM reporter dye like the Cepheid SmartCycler System. ... is comprised of a series of easy-to-use primer ...
... The Stratus CS Analyzer, designed for Acute Care ... your laboratory and near patient setting. It's a ... or D-Dimer results from a whole blood sample ... 3 step process load sample and rotor, ...
Medicine Products: